Elamipretide Guide (2026)
Complete Guide & Evidence (2026)
Mitochondria-targeted tetrapeptide (SS-31/Bendavia) that stabilizes cardiolipin in the inner mitochondrial membrane.
The Mitochondrial Mechanism
Cardiolipin Stabilization
Binds to cardiolipin in inner mitochondrial membrane. Protects from oxidative degradation. Restores cristae architecture for efficient ATP production
Electron Transport Chain
Improves Complex I and Complex III efficiency. Reduces electron leak and superoxide generation. Increases ATP:ADP ratio in deficient cells
ROS Reduction
Directly quenches mitochondrial reactive oxygen species. Reduces oxidative stress in cardiomyocytes. Protects against ischemia-reperfusion injury
Why Cardiolipin Matters
Cardiolipin is found only in the inner mitochondrial membrane and is essential for cristae shape — the folds that house ATP synthase. When cardiolipin is damaged by oxidative stress, cristae flatten,
Clinical Trial Snapshots
Six-minute walk test improvement in TAZPOWER trial for Barth syndrome patients.
Subcutaneous dose used in Phase 2 cardiac trials (Barth syndrome, heart failure).
Active Phase 1–3 trials studying Barth syndrome, heart failure, and mitochondrial myopathy.
Elamipretide Protocol Overview
Note: Elamipretide has not been FDA approved. It is an investigational drug. Clinical trial participation is the safest way to access it. Research-grade versions require CoA verification and sterile reconstitution.
Vital Protocol FAQs
What is elamipretide (SS-31)?
Elamipretide (also known as SS-31 or Bendavia) is a mitochondria-targeted tetrapeptide (D-Arg-2'6'-dimethylTyr-Lys-Phe-NH2) that specifically accumulates in the inner mitochondrial membrane. It works
What conditions is elamipretide being studied for?
Elamipretide has shown promising results in Phase 2 trials for Barth syndrome (a rare genetic heart condition), heart failure with reduced ejection fraction, and mitochondrial myopathy. In a Phase 2 t
What is the elamipretide dosing protocol?
Clinical trial doses for Barth syndrome and heart failure used subcutaneous infusions of 0.05–0.25 mg/kg/day. Research protocols in the biohacking community typically use 5–10 mg subcutaneous daily. E
What are elamipretide's effects on exercise capacity?
In the TAZPOWER trial for Barth syndrome patients, elamipretide significantly improved the 6-minute walk test (exercise capacity) vs. placebo. In heart failure studies, improvements in left ventricula
Guide FAQs
Mitochondria-targeted tetrapeptide (SS-31/Bendavia) that stabilizes cardiolipin in the inner mitochondrial membrane.
Yes. Shotlee supports tracking Elamipretide doses, side effects, and health metrics. It is free to use.
References
Track Your Elamipretide Protocol in Shotlee
Free dose logging, side effect tracking, and health metric monitoring for your complete protocol.
🚀 Use Shotlee for Free